A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2018; you can also visit the original URL.
The file type is application/pdf.
The Present Status of LAK Cell plus IL-2 Immunotherapy for Malignant Gliomas(What is the Best Treatment for Malignant Gliomas?)
LAK療法を中心とした免疫療法の現状(<特集>悪性神経膠腫の最良の治療はなにか)
1992
Japanese Journal of Neurosurgery
LAK療法を中心とした免疫療法の現状(<特集>悪性神経膠腫の最良の治療はなにか)
Preserved Fulltext
The JapaneseCongress of Neurological Surgeons g ttkttttttt.tt-..tt..mat"mees.vat LAK asMe pPJN L ttijeRasaxCDza)Lk iis m bl -4x er rz maN [l] wapt fiEifi-#k fi Using interleukin-2 (IL-2), lymphokine-activated killer (LAK) cells were induced from the lymphocytes of patients with malignant gliomas and their killing activity examined, The mean LAK activity was found to be 54.4 ±
doi:10.7887/jcns.1.110
fatcat:e77g4yhuevd2tmevqi4r54ddwq